Amneal Pharmaceuticals

Amneal Pharmaceuticals

Pharmaceutical Manufacturing

Bridgewater, New Jersey 185,488 followers

We make healthy possible.

About us

Amneal (NASDAQ: AMRX) is rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Our family delivers for yours through a robust U.S. generics business, a growing branded business and deepening portfolios in injectables, biosimilars and select international markets. We’ve bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. And we invest substantially in our people through leadership development and employee well-being programs – all so we can deliver even more value. We are Amneal and We make healthy possible. Content is for informational purposes only and 3rd party content does not reflect Amneal’s opinions. Amneal has the right to remove comments that violate another’s copyright or intellectual property, mention an Amneal product, use profanity or are defamatory, promote and solicit for third-party sites, initiatives, or products, or are factually inaccurate or misleading or spam. Amneal recommends that you consult with your healthcare provider regarding personal health matters. To report a product complaint or adverse event related to an Amneal product, contact Drug Safety at 877-835-5472, option 3 or drugsafety@amneal.com. If you are currently experiencing a life-threatening event, please immediately contact 911.

Industry
Pharmaceutical Manufacturing
Company size
5,001-10,000 employees
Headquarters
Bridgewater, New Jersey
Type
Public Company
Founded
2002

Locations

  • Primary

    400 Crossing Boulevard

    Bridgewater, New Jersey 08807, US

    Get directions

Employees at Amneal Pharmaceuticals

Updates

Similar pages

Browse jobs

Stock

AMRX

NASDAQ

20 minutes delay

$8.49

0.02 (0.236%)

Open
8.52
Low
8.46
High
8.589

Data from Refinitiv

See more info on Bing

Funding

Amneal Pharmaceuticals 3 total rounds

Last Round

Post IPO debt

US$ 2.4B

See more info on crunchbase